Quality of End-of-Life Cancer Care in Canada: A 12-Year Retrospective Analysis of Three Provinces’ Administrative Health Care Data Evaluating Changes over Time

Amanda Farah Khan 1, Hsien Seow 2, Rinku Sutradhar 3, Stuart Peacock 4, Kelvin Kar-Wing Chan 5, Fred Burge 6, Kim McGrail 7, Adam Raymakers 8, Beverley Lawson 6 and Lisa Barbera 1,*

Abstract: This retrospective cohort study of cancer decedents during 2004–2015 examined end-of-life cancer care quality indicators (QIs) in the provinces of British Columbia (BC), Ontario, and Nova Scotia (NS). These included: emergency department use, in-patient hospitalization, intensive care unit admissions, physician house calls, home care visits, and death experienced in hospital. Ontario saw the greatest 12-year decrease in in-hospital deaths from 52.8% to 41.1%. Hospitalization rates within 30 days of death decreased in Ontario, increased in NS, and remained the same in BC. Ontario’s usage of aggressive end-of-life measures changed very little, while BC increased their utilization rates. Supportive care use increased in both NS and Ontario. Those who were male or living in a lower income/smaller community (in Ontario) were associated with a decreased likelihood of receiving supportive care. Despite the shift in focus to providing hospice and home care services, approximately 50% of oncology patients are still dying in hospital and 11.7% of patients overall are subject to aggressive care measures that may be out of line with their desire for comfort care. Supportive care use is increasing, but providers must ensure that Canadians are connected to palliative services, as its utilization improves a wide variety of outcomes.

Keywords: palliative care; quality indicators; health services research; cancer care; end of life

1. Introduction

Quality indicators are measurable items of health care performance that can be used to identify effective health care interventions or pinpoint areas of concern. For those with cancer, patient-defined outcomes that are important at the end of life include being physically independent for as long as possible, having adequate symptom control, spending time with friends and family, and dying at home or outside of hospital [1]. Patients who experience poor end of life (EOL) care are those who suffer from pain, are subjected to treatments that are overly burdensome, have their emotional/spiritual needs go unmet, or die in a setting outside of their home. In addition, their caregivers are often less able to move on after their death [1–3].
Administrative health care data has been employed to understand quality indicators of EOL care in numerous countries, such as the United States, Japan, Sweden, Belgium, and the United Kingdom [4–7]. However, the specific quality indicators used vary, which limits the ability to compare quality across services or settings [8]. In light of this, a systematic review published by Henson et al. evaluated 260 unique quality indicators of cancer care and found that of these, only 80 quality indicators received adequate testing to be appropriate for performance metrics. Furthermore, only 15 of these 80 quality indicators were highlighted as being scientifically sound and applicable across multiple care settings and domains of care [8].

Many jurisdictions in Canada have made commitments to improve end-of-life care, with a focus on more patient- and family-centered decisions and more support for palliative care [9]. As a result, we hypothesized that hospital deaths and other indicators of aggressive care would decrease and that indicators of supportive care would increase over the past decade. However, whether these commitments have in fact translated into tangible, measurable improvements in quality indicators needs to be elucidated. For instance, a 2015 Quality of Death Index report by the Economist Intelligence Unit showed that Canada slipped from 9th to 11th out of 80 countries based on availability, affordability, and quality of palliative care [10]. This paper analyzes end-of-life care for people dying of cancer across three Canadian provinces, over a 12-year time period, to determine whether there are changes in palliative care practices over time in several of the validated QIs outlined by Henson et al.

2. Materials and Methods
2.1. Population and Study Design

This cohort study retrospectively studied patients with the known cause of death attributable to cancer, between 1 April 2004 and 31 March 2015, across three different Canadian provinces: British Columbia (BC), Ontario, and Nova Scotia. The total population of these provinces together comprises 55% of the Canadian population as a whole. Exclusion factors included patients who were less than 18 years of age at time of death and those whose health card number was deemed invalid. In Ontario, only 624 patients were excluded due to these factors. Excluded patients for Nova Scotia and British Columbia were not obtained due to the lack of access to this information in the data request process.

2.2. Data Sources

All deaths attributed to a cancer diagnosis were identified from each province’s cancer registry. This included the BC Cancer Agency, the Ontario Cancer Registry, and the Nova Scotia Cancer Registry [11]. All registries utilized capture at least 90% of all new cancer cases for their respective province. Patient health card numbers were used to link cases to administrative health databases so that patient health services at EOL could be obtained. Data could not be analyzed in aggregate across provinces as this was not allowed due to administrative health databases so that patient health services at EOL could be obtained. Instead, data was analyzed by province and provincial rates compared to each other.

The databases used included the Discharge Abstract Database (which is overseen by the Canadian Institute for Health Information), provincial physician billing claims, and homecare databases [11–13].

Demographic information for Nova Scotia alone was obtained through that province’s cancer registry; for Ontario and BC, it was recorded from public health insurance records. The Statistics Canada 2006 national census was used to obtain neighborhood income and community size. A modified Deyo-Charlson Comorbidity Index (DCCI) score was computed using ICD10 codes from 24 to 12 months prior to death to analyze predicted mortality [14]. The modified DCCI for this analysis excluded points allotted to cancer. Data acquisition for each reported indicator is the same as previous manuscripts in order to facilitate comparison [2].
2.3. Health Service Quality Indicators

QIs that are widely used and identified as important to quality care at EOL by Henson et al. were considered for this study [8]. Those that were suitable for measurement using administrative data were included, specifically patients that had \( \geq 1 \) new hospitalizations in the last month of life, \( \geq 1 \) emergency department visits in the last 2 weeks or 30 days of life, an intensive care unit admission in the last month of life, and/or \( \geq 1 \) physician house calls in the last 2 weeks of life. In addition, receipt of palliative homecare, nursing, and supportive services were examined among those who were eligible to receive such services during the last 6 months of life. Denominators for each indicator only included those at risk of the outcome being measured. For example, patients admitted for the entire final 30 days of life could not experience an ED visit and were excluded from the denominator of that indicator.

Aggregate measures of aggressive or supportive care were created by combining selected indicators, as done in prior research [2]. “Aggressive care” was defined as any one of or a combination of the following: two or more emergency department visits in the last 30 days before death, at least two new hospitalizations within 30 days of death, or an ICU admission within the last 30 days of life. “Supportive care” was defined as having at least one of or a combination of the following: a physician house call in the last 2 weeks before death, or a palliative nursing or personal support visit at home in the last 6 months before death. Supportive care data for BC was not included, as data for this measure was incomplete.

2.4. Statistical Analysis

Population characteristics at death were analyzed using descriptive statistics for each province. Overall crude and standardized rates for each indicator were calculated to allow interprovincial comparisons for the years 2004–2015. Crude rates were calculated as the proportion of patients who met that indicator’s definition. Standardized rates were calculated using the direct method and compared to 2014/2015 for the standard populations [2]. Two multivariable logistic regression models were created to understand what factors were associated with a patient receiving either aggressive or supportive care. Year of death was the main exposure, and other co-variates in the adjusted models were controlled. These co-variates included age, sex, score on the modified Deyo-Charlson comorbidity index, cancer type, neighborhood income quintile, community size, and health service region. Age was factored in as a continuous variable while the other variables were factored as categorical. Odds ratios (ORs) have been reported with 95% confidence intervals (CIs). Cochran–Armitage trend test \( p \)-values (two-sided) were calculated for all trend data. For cancer type, lung cancer was chosen as the reference cancer group because it was the most common cancer type and, therefore, the largest cancer subgroup.

Statistical analyses were performed using SAS (SAS Institute, Cary, NC, USA), R (The R Foundation, Vienna, Austria), and Microsoft Excel (Redmond, WA, USA). NumPy was utilized for data visualization [15]. The Hamilton Integrated Research Ethics Board (#3039) approved this study for Ontario data with the provision that all research must be conducted in accordance with the policies of the Institute for Clinical Evaluative Sciences. The Nova Scotia Health research ethics board, the Nova Scotia Department of Health and Wellness, and Health Data Nova Scotia approved the collection of data in that province, while the University of British Columbia (BC) Cancer Agency Research Ethics Board provided authorization in British Columbia.

3. Results
3.1. Demographics

In total, 376,108 patients who died from their cancer were included in this study and subsequently analyzed (Table A1). The mean age at death was 71.9 ± 12.7 years, and 46.9% of our study population were women. Overall age, sex, income, and cancer types were similar across the three different provinces. However, of note is that British Columbia
had a slightly lower percentage of patients with a score of at least 1 on the Deyo-Charlson comorbidity index (34% compared to 39.4% in Ontario and 41.1% in Nova Scotia), and Nova Scotians live in smaller-sized communities.

3.2. Quality Indicators

Crude and standardized quality indicator rates (for all study years overall) are shown in the Appendix A in Table A2, by province. Overall, 50.1% of patients died in hospital; British Columbia had the lowest standardized rate of such deaths at 47.7%, whereas Nova Scotia had the highest rate at 66.5%. Patients with a new admission to hospital within 30 days of death ranged across provinces, from 49.5% in British Columbia to 57.6% in both Ontario and Nova Scotia. Rates of admission to the ICU were lowest in Nova Scotia at 4.0%, compared to 8.1% in Ontario. Comparing emergency department (ED) visit data within the last 30 days of death, British Columbia had the lowest use at 38.6%, whereas Ontario had the highest at 46.7%. Overall, 11.7% of all patients received aggressive care, with British Columbia having the lowest rate at 8.3%, with the highest in Ontario at 13.2%. Nova Scotia had the highest rate of supportive care usage between the two provinces with complete data at 55.3% (Ontario was 49.8%). Comparing Nova Scotia and Ontario, 54.7% of Nova Scotians received some form of palliative care at home vs. 46.7% of Ontarians, while 12.4% of Nova Scotians were visited by a physician within 2 weeks of death vs. 22.5% of Ontarians. British Columbia was excluded from the supportive care analysis due to incomplete data.

3.3. Data Trends over Time

Data from 2004 to 2015 were analyzed for yearly trends over time. In terms of death experienced in an acute care hospital, Ontario experienced the greatest 12-year time span decline from 52.8% in 2004 to 41.1% in 2015 (p < 0.0001). British Columbia also experienced a decline from 54.9% to 45.2% in the same time span (Figure 1, top, p < 0.0001), while Nova Scotia experienced an increase in that time frame from 65% to 68.6% (p < 0.0001). In regard to hospitalization rates within 30 days of death, Ontario experienced the largest change, decreasing from 59.7% in 2004 to 53.2% in 2015 (p < 0.0001). Both Nova Scotia and BC rates were relatively stable during this time span (p > 0.05). Emergency room visits within 2 weeks of death were stable from 2004 to 2015 for Ontario (from 46.1% to 45.5%, p = 0.0001) and Nova Scotia (41.3% to 41.0%, p = 0.0718). British Columbia experienced an increase in ED visits from 36.7% to 42.0% (p < 0.0001).

By province, Ontario and BC largely remained consistent in their use of aggressive care measures (from 13.59% in 2004 to 13.43% in 2015, p = 0.2152, and from 7.8% in 2004 to 8.73% in 2015, p < 0.0001 respectively), while Nova Scotia decreased their use from 11.9% to 9.4% in the same time span (p < 0.0001). For the remaining years of analysis, Ontario saw an increase in supportive care usage from 44.0% in 2005 to 57.6% in 2015 (p < 0.0001). Nova Scotia also experienced an increase, from 54.3% in 2006 to 57.6% in 2015 (p < 0.0001).

3.4. Multivariable Logistic Regression Models

The regression analyses showed that younger age, male sex, and residence in smaller-sized communities were all associated with an increased likelihood of receiving aggressive care (Table A3 and Figure 2)—an observation that was consistent for all provinces. In Ontario, living in a low-income neighborhood was also associated with receipt of aggressive care, whereas those with breast (OR of 0.71, 95% CI 0.82–0.99), colorectal (OR of 0.93, 95% CI 0.89–0.97), or prostate cancer (OR of 0.63, 95% 0.59-0.67) were less likely to receive aggressive care when compared to patients with lung cancer.
In total, 376,108 patients who died from their cancer were included in this study and all three provinces of Canada. Over the years, the number of patients deceased increased from 2004 to 2015. Ontario saw the greatest decrease in deaths, from 52.8% in 2004 to 41.1% in 2015. Ontario experienced the largest amount of change in hospitalizations within 30 days of death, decreasing from 59.7% in 2004 to 53.2% in 2015. Emergency room visits within 2 weeks of death stayed the same for Ontario and Nova Scotia, while British Columbia experienced an increase from 2004 to 2015. p-values reported are from the Cochran–Armitage trend test (two-sided); * denotes values that are statistically significant.

Figure 1. Death in acute care hospital (top), new hospitalizations within 30 days of death (middle), and one or more ED visits within 2 weeks of death (bottom) data over time from 2004 to 2015. In terms of death experienced in an acute care hospital, Ontario saw the greatest decrease, from 52.8% in 2004 to 41.1% in 2015. Ontario experienced the largest amount of change in hospitalizations within 30 days of death, decreasing from 59.7% in 2004 to 53.2% in 2015. Emergency room visits within 2 weeks of death stayed the same for Ontario and Nova Scotia, while British Columbia experienced an increase from 2004 to 2015. p-values reported are from the Cochran–Armitage trend test (two-sided); * denotes values that are statistically significant.
In terms of analysis by year (Table A3 and Figure 3), understanding the trends in the utilization of aggressive care is not as straightforward as the supportive care model. Nova Scotians over time utilized aggressive care less, which correlated to decreased odds ratios from 2004 to 2015. Ontario experienced little change in the standardized rates of aggressive care usage, which is consistent with the relatively steady odds ratios in the multivariable study. BC data shows the most variability in standardized rate over time, which is reflected in the variation in odds ratios in the regression model for this province.

Factors associated with an increased likelihood of receiving supportive care amongst the three provinces were younger age and female sex (Table A4 and Figure 2). Living in a larger community was also associated with a higher likelihood of receiving supportive care. In Ontario, those with a score of at least 1 on the Deyo-Charlson Comorbidity Index were less likely to receive supportive care. Of note, compared with people in the highest-income neighborhoods, people living in the lowest-income neighborhoods had a 0.74–0.80 (CI of 1.04 to 1.13) likelihood of receiving supportive care. Also in Ontario, those diagnosed with breast cancer had a higher likelihood of receiving supportive care when compared to patients with lung cancer. In Nova Scotia those with colorectal cancer had an increased likelihood of receiving supportive care than those with lung cancer. In terms of analysis by year (Table A4), access to supportive care improved over time for both Ontario and Nova Scotia, as odds ratios trend upwards toward 2015 as the reference point, which parallels the overall improvement in standardized rates plotted in Figure 2.
Figure 3. Aggressive care (top) and supportive care (bottom) data over time from 2004 to 2015. In Ontario, there was little overall change in the overall rate of receiving aggressive care (from 13.6% in 2004 to 13.4% in 2015). Aggressive care utilization dropped in this time in Nova Scotia from 11.9% in 2004 to 9.4% in 2015. British Columbia’s aggressive care utilization slightly increased from 7.8% in 2004 to 8.7% in 2015. Supportive care use rose in Ontario from 44% in 2004 to 57.6% in 2015. Nova Scotia’s utilization slightly increased from 54.3% in 2006 to 57.6% in 2015. \( p \)-values reported are from the Cochran–Armitage trend test (two-sided); * denotes values that are statistically significant. Ontario does not have reported data for 2004 and Nova Scotia does not have data for both 2004 and 2005.

4. Discussion

We present a 12-year analysis of commonly defined quality indicators in EOL care across three Canadian provinces using administrative health care data to create identically defined cohorts. This paper represents the most comprehensive and current analysis of end-of-life QIs for cancer patients in Canada. It provides longitudinal data including multiple care settings, which have been prior research gaps. Examining quality specifically among cancer patients is important because cancer care has a long history of incorporating palliation, and cancer has a more defined end-of-life trajectory compared to other terminal chronic illnesses, such as COPD, which may mean greater access to supportive care at EOL [15]. Patients with end-stage cancer also often have high rates of hospitalization, but the use of aggressive end-of-life care is often discordant with the desires of the general population [16]. Yet, across many countries, most patient deaths still occur in an institutional setting instead of at home [17,18]. While acute care hospitals serve a role in managing the needs of oncology patients at the end of life, quality end of life care can be provided in other settings, including at home or in hospice by family physicians, home care nurses, and personal care workers [19].

In our analysis, we found inconsistent evidence of improvement. Fewer Canadians are dying in hospital over time, particularly in BC and Ontario. Hospitalization rates within 30 days of death in Ontario have also improved over time, possibly due to a
funding strategy that enhanced access to end-of-life home care services, but to define a conclusive cause of improvement is a complex and nuanced discussion [20]. During the same period, Nova Scotia’s hospitalization rate worsened, while BC largely remained the same. Reducing unnecessary hospitalizations is of particular interest to publicly funded health care systems, as the overall cost of cancer care is rising, with a high proportion of dollars being spent on end-of-life care [16]. In NS and Ontario, indicators related to supportive care also seem to be improving. Again, these may reflect investments made into these sectors in combination with increased awareness and emphasis on the role supportive care services can play, but further research into the causality is needed.

Regardless of any observed improvements over time, all indicators remain worse than previously published Canadian benchmarks [21]. For example, the benchmark rate (based on regional top performers) for death in hospital was 38%, yet in our analysis, all three provinces were consistently worse than these benchmarks. This was also true for other indicators. The benchmark rate for ED visits in the last 30 days was 34%, ICU admissions in the last 30 days was 2%, house calls in the last 2 weeks was 34%, and home care in the last 6 months was 63%. This indicates that while some gains have been made, opportunities for further improvement remain. In contrast to studies from other countries, Canadian in-hospital death rates remain higher than those in the United States, but are similar to those in Taiwan and Singapore, and lower than those in Norway [22–24].

Our multivariable logistic regression models showed that patients who were male, younger, and living in poorer neighborhoods or smaller communities across the three provinces are less likely to receive supportive care services. This is an important finding, as research shows that Canadians who come from low-income, rural, or new immigrant backgrounds have poorer access to high-quality palliative care [25,26]. Our data remains consistent with data reported by other Canadian studies in regards to hospitalization rates and socioeconomic and location discrepancies in aggressive vs. supportive care [22,27].

Limitations of this study include the fact that not all data were available in each province. For example, chemotherapy information is not available from Nova Scotia and is available from very different sources in Ontario (claims) and BC (pharmacy data); thus, chemotherapy use was not included in our study. Similarly, there were differences in data sources for other measures such as ED that compromised comparability. For this reason, inpatient hospitalization data were used to identify patients admitted to hospital via the ED, which was consistent but did not count ED visits that did not lead to hospitalization. Lastly, the indicators themselves have limitations and may not capture important aspects of care. For example, it did not reflect patient quality-of-life, caregiver burden, or preferences. There is also inconsistent or unavailable data for other QIs that Henson et al. outlined as important, such as physical aspects of care (including those who received tube or intravenous feeding in the month before death) or the number of patients who received opioids in the month before death [8].

5. Conclusions

This work highlights 12 years of quality EOL data across three different Canadian provinces with identically identified cohorts and commonly defined QIs. We have found strong evidence that despite the shift in focus to providing earlier EOL care to oncology patients with supportive care measures, approximately half of oncology patients are still dying in hospital, although it is improving. Furthermore, 11.7% of patients are subject to aggressive care measures that may be out of line with their desire for comfort care in a non-hospital setting. Our study highlights that over the 12-year time span studied, little change occurred in the use of aggressive care services and ED visits within the last 2 weeks of life. However, supportive care use is on the rise, with Ontarians increasing their use in our study time frame. Access to robust palliative care services is important for symptom management, particularly at end of life. By not connecting patients to palliative and supportive care services at end of life, they may miss out on evidence-based interventions and services that are known to improve a wide variety of outcomes.
Author Contributions: Conceptualization, H.S., R.S., S.P., K.K.-W.C., F.B., K.M., B.L., A.R. and L.B.; methodology, A.F.K., H.S., R.S., A.R. and L.B.; formal analysis, A.F.K., H.S., R.S., B.L. and A.R.; investigation, A.F.K., H.S., R.S., S.P., K.K.-W.C., F.B., K.M., B.L., A.R. and L.B.; resources, A.F.K., H.S., R.S., S.P., K.K.-W.C., F.B., K.M., B.L., A.R. and L.B.; data curation, A.F.K., H.S., R.S., S.P., K.K.-W.C., F.B., K.M., B.L., A.R. and L.B.; writing—original draft preparation, A.F.K., H.S. and L.B.; writing—review and editing, A.F.K., H.S., R.S., S.P., K.K.-W.C., F.B., K.M., B.L., A.R. and L.B.; visualization, A.F.K.; supervision, H.S. and L.B.; project administration, H.S. and L.B.; funding acquisition, H.S. and L.B. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC receives core funding from the Canadian Cancer Society Research Institute (Grant No. 2020-706936). In Ontario, the study used databases maintained by the Institute for Clinical Evaluative Sciences, which receives funding from the Ontario Ministry of Health and Long-Term Care.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) in Ontario by the Hamilton Integrated Research Ethics Board (#3039), conducted in accordance with the strict confidentiality and privacy policies of the Institute for Clinical Evaluative Sciences. In Nova Scotia, the study was approved by the Nova Scotia Health research ethics board, the Nova Scotia Department of Health and Wellness, and Health Data Nova Scotia. The University of British Columbia (BC) Cancer Agency Research Ethics Board provided approval in British Columbia.

Informed Consent Statement: Individual patient consent was waived as data was analyzed in aggregate from each province’s health data collection authority.

Data Availability Statement: All data used in the preparation of this paper is governed by each respective province and is not publicly available due to privacy and regulations governing the use of these data.

Acknowledgments: The authors thank Anastasia Gayowsky and Urun Erbas-Oz for analysis support and Erin O’Leary for project management. Parts of this material are based on data and information compiled by CIHI, Cancer Care Ontario (CCO), and Ontario Registrar General (ORG) information on deaths, the original source of which is ServiceOntario. The BC Cancer Agency and the British Columbia Ministry of Health approved access to and use of the data held by Population Data BC for this study. Portions of the data used in this report were made available by the Nova Scotia Department of Health and Wellness and the Population Health Research Unit (now known as Health Data Nova Scotia) of Dalhousie University. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding and data provision sources.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Table A1. Socio-demographic data by province, 2004–2015.

| Characteristic | BC        | ON        | NS         | Overall    |
|---------------|-----------|-----------|------------|-----------|
|               | n         | %         | n          | %         | n         | %         |
| Study Population | 104,106  | 242,556   | 29,446     | 376,108   |
| Age group     |           |           |            |           |
| 18–49 Years  | 4984      | 4.8       | 12,782     | 5.3       | 1401      | 4.8       | 19,167     | 5.1   |
| 50–79 Years  | 65,234    | 62.7      | 154,257    | 63.6      | 18,877    | 64.1      | 238,368    | 63.4  |
| 80+ Years    | 33,878    | 32.5      | 75,517     | 31.1      | 9168      | 31.1      | 118,563    | 31.5  |
| Sex           |           |           |            |           |
| Male          | 55,381    | 53.2      | 128,772    | 53.1      | 15,559    | 52.8      | 199,712    | 53.1  |
| Income quintile |         |           |            |           |
| 1 (lowest)   | 23,094    | 23.1      | 51,526     | 21.3      | 6300      | 21.7      | 80,902     | 21.9  |
| 2             | 20,459    | 20.5      | 51,569     | 21.4      | 6170      | 21.3      | 78,198     | 21.1  |
| 3             | 19,380    | 19.4      | 47,424     | 19.6      | 5864      | 20.2      | 72,668     | 19.6  |
| 4             | 18,418    | 18.4      | 46,496     | 19.3      | 5595      | 19.3      | 70,509     | 19.0  |
| 5 (highest)  | 18,532    | 18.6      | 44,382     | 18.4      | 5070      | 17.5      | 67,984     | 18.4  |
Table A1. Cont.

| Characteristic                  | BC         | ON         | NS         | Overall |
|--------------------------------|------------|------------|------------|---------|
|                                | n          | n          | n          | n       | n          | n          |
|                                | %          | %          | %          | %       | %          | %          |
| Community size                 |            |            |            |         |            |            |
| >1,500,000                     | 44,829     | 43.8       | 80,513     | 33.2    | 0          | 0          | 125,342    | 33.5    |
| 500,000–1,499,999              | 0          | 0          | 31,359     | 12.9    | 0          | 0          | 45,255     | 12.1    |
| 100,000–499,999                | 18,050     | 17.6       | 66,341     | 27.4    | 13,896     | 47.8       | 87,860     | 23.5    |
| 10,000–99,999                  | 23,126     | 22.6       | 27,855     | 11.5    | 3469       | 11.9       | 62,681     | 16.8    |
| <10,000                        | 16,363     | 16.0       | 36,306     | 15.0    | 11,700     | 40.3       | 53,050     | 14.2    |
| Cancer type                    |            |            |            |         |            |            |
| Brain                          | 2856       | 2.8        | 6679       | 2.8     | 713        | 2.4        | 10,248     | 2.7     |
| Breast                         | 7245       | 7.0        | 18,908     | 7.8     | 1949       | 6.6        | 28,102     | 7.5     |
| Colorectal                     | 12,781     | 12.4       | 30,397     | 12.5    | 3964       | 13.5       | 47,142     | 12.6    |
| Gynecological                  | 4483       | 4.3        | 11,138     | 4.6     | 1176       | 4.0        | 16,797     | 4.5     |
| Head and Neck                  | 2394       | 2.3        | 6650       | 2.7     | 625        | 2.1        | 9669       | 2.6     |
| Hematology                     | 9616       | 9.3        | 25,098     | 10.3    | 2190       | 7.4        | 36,904     | 9.8     |
| Lung                           | 26,447     | 25.7       | 66,784     | 27.5    | 8337       | 28.3       | 101,568    | 27.1    |
| Other                          | 13,164     | 12.8       | 21,879     | 9.0     | 4264       | 14.5       | 39,307     | 10.5    |
| Other Gastrointestinal         | 11,864     | 11.5       | 26,497     | 10.9    | 2998       | 10.2       | 41,359     | 11.0    |
| Other Genitourinary            | 5952       | 5.8        | 12,778     | 5.3     | 1705       | 5.8        | 20,435     | 5.4     |
| Prostate                       | 6304       | 6.1        | 15,748     | 6.5     | 1825       | 5.2        | 23,577     | 6.3     |

Score on the Deyo-Charlson comorbidity index (from 24 months to 12 months before death)

|                          | BC          | ON          | NS          | Overall |
|--------------------------|-------------|-------------|-------------|---------|
| 0                        | 55,008      | 52.8        | 116,225     | 47.9    | 14,492     | 49.2       | 185,725    | 49.4    |
| 1+                       | 35,401      | 34.0        | 95,510      | 39.4    | 12,098     | 41.1       | 143,009    | 38.0    |
| Missing                  | 13,697      | 13.2        | 30,821      | 12.7    | 2859       | 9.7        | 47,377     | 12.6    |

Table A2. Quality indicator rates by province, 2004–2015.

| Indicator                                      | BC n     | BC %     | ON n     | ON %     | NS n     | NS %     | Overall n | Overall % |
|------------------------------------------------|----------|----------|----------|----------|----------|----------|-----------|-----------|
| Death in acute care hospital or bed (overall)  |          |          |          |          |          |          |           |           |
| New Hospitalization within 30 days of death    |          |          |          |          |          |          |           |           |
| ≥1 New admission                               |          |          |          |          |          |          |           |           |
| With new intensive care unit admission         | 51,701   | 49.5     | 129,091  | 57.6     | 16,857   | 57.6     | 197,649   | 55.4     |
| All eligible patients (excluding those in hospital for the last 30 days of life) | 104,014 | 100.2   | 104,014  | 100.2   | 104,014  | 100.2   | 312,042  | 100.0    |
| Emergency department visit within 30 days of death | 40,200  | 38.5     | 104,428  | 46.7     | 11,571   | 39.7     | 156,199   | 43.8     |
| All eligible patients (excluding those in hospital for the last 30 days of life) | 104,014 | 100.2   | 104,014  | 100.2   | 104,014  | 100.2   | 312,042  | 100.0    |
| Home visit within 6 months of death            |          |          |          |          |          |          |           |           |
| By a registered nurse                          | 156,118  | 64.9     | 12,804   | 51.6     | 38,534   | 54.9     | 157,456   | 55.0     |
| By a personal support worker                   | 98,992   | 41.2     | 10,047   | 40.5     | 198,949  | 41.2     | 318,949   | 41.2     |
| Having a palliative nursing or personal support worker home care visit within 6 months of death | 98,534 | 46.0     | 13,514   | 54.9     |          |          |           |           |
| All eligible patients (excluding those in hospital for the last 30 days of life) | 240,500 | 100.0   | 240,500  | 100.0   | 240,500  | 100.0   | 721,500  | 100.0    |
| Physician house call within 2 weeks of death   |          |          |          |          |          |          |           |           |
| Patients who received a house call              | 53,521   | 27.3     | 53,521   | 27.3     | 3586     | 12.4     | 93,496    | 27.7     |
| All eligible patients (excluding those in hospital for the last 14 days of life) | 196,061 | 100.0   | 196,061  | 100.0   | 196,061  | 100.0   | 590,182  | 100.0    |
### Table A2. Cont.

| Indicator                                                                 | BC       | ON       | NS       | Overall  |
|---------------------------------------------------------------------------|----------|----------|----------|----------|
|                                                                           | $n$      | $\%$     | $n$      | $\%$     | $n$      | $\%$     | $n$      | $\%$     |
| **Aggressive care**                                                       |          |          |          |          |
| At least one care factor listed below:                                    | 8776     | 8.3      | 29,802   | 13.2     | 3283     | 11.1     | 41,861   | 11.7     |
| Having at least 2 ED visits within 30 days of death                       | 3872     | 10.20    | 1000     | 1000     | 1000     | 1000     | 1000     | 1000     |
| Having at least 2 new hospitalizations within 30 days of death           | 6913     | 15.02    | 2235     | 2235     | 2235     | 2235     | 2235     | 2235     |
| Being in the ICU within 30 days of death                                 | 7122     | 18.293   | 1181     | 1181     | 1181     | 1181     | 26,596   | 7.5      |
| All eligible patients (excluding those in hospital for the last 30 days of life) | 104,014  | 223,325  | 29,109   | 356,448  | 356,448  | 356,448  |          |          |
| **Supportive care**                                                       |          |          |          |          |
| Utilizing at least one service below:                                     | 107,353  | 50.1     | 13,701   | 55.3     |          |          |          |          |
| Having a physician house call within 2 weeks of death                    | 48,238   | 22.5     | 3586     | 2586     |          |          |          |          |
| Having palliative nursing or personal support worker home care visit within 6 months of death | 98,534   | 46.0     | 13,514   | 54.7     |          |          |          |          |
| All eligible patients (excluding those in hospital for the last 6 months of life) | 214,389  | 24,630   |          |          |          |          |          |          |

### Table A3. Multivariable logistic regression model for aggressive care, 2004–2015.

| Factor                                           | BC 95% CL | OR   | Lower | Upper | OR   | Lower | Upper | OR   | Lower | Upper |
|---------------------------------------------------|------------|------|-------|-------|------|-------|-------|------|-------|-------|
| Age (years)                                       | 0.98       | 0.97 | 0.98  | 0.98  | 0.98 | 0.98  | 0.98  | 0.98 | 0.98  | 0.98  |
| Male (reference: Female)                          | 1.26       | 1.20 | 1.30  | 1.31  | 1.27 | 1.34  | 1.38  | 1.28 | 1.5   |       |
| Charlson comorbidity index 1+ (reference: 0 or missing) | 0.99       | 0.94 | 1.03  | 0.95  | 0.91 | 0.98  | 1.04  | 0.93 | 1.16  |       |
| Cancer type (reference: Lung)                      |            |      |       |       |      |       |       |      |       |       |
| Breast                                            | 0.91       | 0.82 | 0.99  | 0.71  | 0.68 | 0.75  | 0.88  | 0.74 | 1.06  |       |
| Colorectal                                        | 1.03       | 0.96 | 1.11  | 0.93  | 0.89 | 0.97  | 1.02  | 0.9  | 1.15  |       |
| Prostate                                          | 0.73       | 0.66 | 0.82  | 0.63  | 0.59 | 0.67  | 0.69  | 0.56 | 0.85  |       |
| Other                                             | 1.21       | 1.14 | 1.28  | 1.01  | 0.98 | 1.04  | 1.13  | 1.04 | 1.23  |       |
| Neighborhood income quintile (reference: 5, highest) |            |      |       |       |      |       |       |      |       |       |
| 1 (lowest)                                        | 0.94       | 0.88 | 1.01  | 1.09  | 1.04 | 1.13  | 1.01  | 0.89 | 1.14  |       |
| 2                                                 | 0.98       | 0.91 | 1.05  | 1.06  | 1.02 | 1.10  | 1.14  | 1.02 | 1.29  |       |
| 3                                                 | 1.02       | 0.95 | 1.1   | 1.07  | 1.03 | 1.11  | 1.02  | 0.91 | 1.16  |       |
| 4                                                 | 0.96       | 0.89 | 1.03  | 1.05  | 1.013| 1.10  | 1.09  | 0.96 | 1.22  |       |

### Table A4. Multivariable logistic regression model for supportive care, 2004–2015.

| Factor                                           | ON 95% CL | NS (New Health Zone) 95% CL |
|---------------------------------------------------|-----------|----------------------------|
| Age (years)                                       | 0.98      | 0.98                       |
| Male (reference: Female)                          | 0.92      | 0.90                       |
| Charlson comorbidity index 1+ (reference: 0 or missing) | 0.89      | 0.87                       |
### Table A4. Cont.

| Factor                        | ON       | NS (New Health Zone) |               | Lower | Upper | Lower | Upper |
|-------------------------------|----------|----------------------|---------------|-------|-------|-------|-------|
| Cancer type                   |          |                      |               | Lower | Upper | Lower | Upper |
| Breast                        | 1.04     | 1.01                 | 1.08          | 1.02  | 0.91  | 1.14  |       |
| Colorectal                    | 0.92     | 0.89                 | 0.95          | 1.10  | 1.01  | 1.20  |       |
| Prostate                      | 0.84     | 0.80                 | 0.87          | 1.06  | 0.93  | 1.21  |       |
| Other                         | 0.85     | 0.83                 | 0.87          | 0.88  | 0.83  | 0.94  |       |
| Lung                          | 1        | -                    | -             | 1     | -     | -     |       |

Neighborhood income quintile  
(reference: 5, highest)

| Neighborhood income quintile | Lower | Upper | Lower | Upper |
|-------------------------------|-------|-------|-------|-------|
| 1 (lowest)                    | 0.74  | 0.72  | 0.76  | 0.80  | 0.73  | 0.87  |       |
| 2                              | 0.85  | 0.83  | 0.88  | 0.90  | 0.82  | 0.97  |       |
| 3                              | 0.88  | 0.86  | 0.91  | 1.03  | 0.94  | 1.12  |       |
| 4                              | 0.94  | 0.91  | 0.96  | 1.01  | 0.93  | 1.10  |       |

Community size  
(reference: ≥100,000)

| Community size | Lower | Upper | Lower | Upper |
|----------------|-------|-------|-------|-------|
| <10,000        | 0.89  | 0.87  | 0.91  | 0.79  | 0.72  | 0.87  |       |
| 10,000–99,999  | 0.95  | 0.93  | 0.98  | 0.93  | 0.81  | 1.07  |       |

Boldface type indicates significant values, OR = odds ratio, CL = confidence limits.

### References

1. Currow, D.C.; Agar, M.R.; Phillips, J.L. Role of hospice care at the end of life for people with cancer. *J. Clin. Oncol.* 2020, 38, 937–943. [CrossRef] [PubMed]
2. Barbera, L.; Seow, H.; Sutrathrar, R.; Chu, A.; Burge, F.; Fassbender, K.; McGrail, K.; Lawson, B.; Liu, Y.; Pataky, R.; et al. Quality of end-of-life cancer care in Canada: A retrospective four-province study using administrative health care data. *Curr. Oncol.* 2015, 22, 341–355. [CrossRef] [PubMed]
3. Singer, P.A.; Bowman, K.W. Quality end-of-life care: A global perspective. *BMC Palliat. Care* 2002, 1, 4. [CrossRef] [PubMed]
4. De Schroye, R.; Smets, T.; Annemans, L.; Deliens, L.; Giezen, B.; De Gendt, C.; Cohen, J. Applying quality indicators for administrative databases to evaluate end-of-life care for cancer patients in Belgium. *Health Aff.* 2017, 36, 1234–1243. [CrossRef] [PubMed]
5. Marshall, M.N.; Shekelle, P.G.; Davies, H.T.O.; Smith, P.C. Public reporting on quality in the United States and the United Kingdom. *Health Aff.* 2003, 22, 134–148. [CrossRef]
6. Lindskog, M.; Tavelin, B.; Lundström, S. Old age as risk indicator for poor end-of-life care quality—A population-based study of cancer deaths from the Swedish Register of Palliative Care. *Eur. J. Cancer* 2015, 51, 1331–1339. [CrossRef]
7. Miyashita, M.; Nakamura, A.; Morita, T.; Bito, S. Identification of quality indicators of end-of-life cancer care from medical chart review using a modified Delphi method in Japan. *Am. J. Hosp. Palliat. Med.* 2008, 25, 33–38. [CrossRef]
8. Henson, L.A.; Edmonds, P.; Johnston, A.; Johnson, H.E.; Ling, C.N.Y.; Skaletous, A.; Ellis-Smith, C.; Gao, W. Population-Based Quality Indicators for End-of-Life Cancer Care: A Systematic Review. *JAMA Oncol.* 2020, 6, 142–150. [CrossRef]
9. Fowler, R.; Hammer, M. View of End-of-Life Care in Canada. Available online: https://cimonline.ca/index.php/cim/article/view/19723/16336 (accessed on 17 May 2021).
10. Framework on Palliative Care in Canada. Available online: https://www.canada.ca/en/health-canada/services/health-care-system/reports-publications/palliative-care-framework-palliative-care-canada.html (accessed on 6 September 2021).
11. Discharge Abstract Database (Hospital Separations). Available online: https://www.popdata.bc.ca/data/health/dad (accessed on 6 September 2021).
12. Home & Community Care (Continuing Care). Available online: http://www.popdata.bc.ca/data (accessed on 6 September 2021).
13. BC Cancer Registry Data V2. Available online: https://www.popdata.bc.ca/data/health/bccancer (accessed on 6 September 2021).
14. Ladha, K.S.; Zhao, K.; Quraishi, S.A.; Kurth, T.; Eiermann, M.; Kaafarani, H.M.; Klein, E.N.; Seethala, R.; Lee, J. The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients. *BMJ Open* 2015, 5, 8990. [CrossRef]
15. Moens, K.; Higginson, I.J.; Harding, R. Are There Differences in the Prevalence of Palliative Care-Related Problems in People Living with Advanced Cancer and Eight Non-Cancer Conditions? A Systematic Review. *J. Pain Symptom Manag.* 2014, 48, 660–677. [CrossRef]
16. Rocque, G.B.; Barnett, A.E.; Illig, L.C.; Eichkoff, J.C.; Bailey, H.H.; Campbell, T.C.; Stewart, J.A.; Cleary, J.F. Inpatient hospitalization of oncology patients: Are we missing an opportunity for end-of-life care? *J. Oncol. Pract.* 2013, 9, 51–54. [CrossRef]
17. De Roo, M.L.; Miccinesi, G.; Onwuteaka-Philipsen, B.D.; Van Den Noortgate, N.; Van den Block, L.; Bonacchi, A.; Donker, G.A.; Lozano Alonso, J.E.; Moreels, S.; Dелиенс, Л.; et al. Actual and Preferred Place of Death of Home-Dwelling Patients in Four European Countries: Making Sense of Quality Indicators. *PLoS ONE* 2014, 9, e93762. [CrossRef]  
18. Burge, F.; Lawson, B.; Johnston, G.; Asada, Y.; McIntyre, P.F.; Flowerdew, G. Preferred and Actual Location of Death: What Factors Enable a Preferred Home Death? *J. Palliat. Med.* 2015, 18, 1054–1059. [CrossRef]  
19. DeCarlo, K.; Dudgeon, D.; Green, E.; Moxam, R.S.; Rahal, R.; Niu, J.; Bryant, H. Acute care hospitalization near the end of life for cancer patients who die in hospital in Canada. *Curr. Oncol.* 2017, 24, 256–261. [CrossRef]  
20. Seow, H.; Barbera, L.; Howell, D.; Dy, S.M. Did Ontario’s end-of-life care strategy reduce acute care service use? *Healthc. Q.* 2010, 13, 93–100. [CrossRef]  
21. Barbera, L.; Seow, H.; Sutradhar, R.; Chu, A.; Burge, F.; Fassbender, K.; McGrail, K.; Lawson, B.; Liu, Y.; Pataky, R. Quality Indicators of End-of-Life Care in Patients with Cancer: What Rate Is Right? *J. Oncol. Pract.* 2015, 11, e279–e287. [CrossRef]  
22. Tanuseputro, P.; Beach, S.; Chalifoux, M.; Wodchis, W.P.; Hsu, A.T.; Seow, H.; Manuel, D.G. Associations between physician home visits for the dying and place of death: A population-based retrospective cohort study. *PLoS ONE* 2018, 13, e0191322. [CrossRef]  
23. Zhuang, Q.; Lau, Z.Y.; Ong, W.S.; Yang, G.M.; Tan, K.B.; Ong, M.E.H.; Wong, T.H. Sociodemographic and clinical factors for non-hospital deaths among cancer patients: A nationwide population-based cohort study. *PLoS ONE* 2020, 15, e0232219. [CrossRef]  
24. Kalseth, J.; Halvorsen, T. Relationship of place of death with care capacity and accessibility: A multilevel population study of system effects on place of death in Norway. *BMC Health Serv. Res.* 2020, 20, 454. [CrossRef]  
25. Cancers System Performance: 2017 Report. Available online: https://s22457.pcdn.co/wp-content/uploads/2019/12/2017_cancer_system_performance_report_EN.pdf (accessed on 6 September 2021).  
26. Salas, A.S.; Watanabe, S.M.; Tarumi, Y.; Wildeman, T.; Garcia, A.M.H.; Adewale, B.; Duggleby, W. Social disparities and symptom burden in populations with advanced cancer: Specialist palliative care providers’ perspectives. *Support. Care Cancer* 2019, 27, 4733–4744. [CrossRef]  
27. Barbera, L.; Sussman, J.; Viola, R.; Husain, A.; Howell, D.; Librach, S.L.; Walker, H.; Sutradhar, R.; Chartier, C.; Paszat, L. Factors associated with end-of-life health service use in patients dying of cancer. *Healthc. Policy* 2010, 5, e125. [CrossRef] [PubMed]